Compare SBFM & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBFM | APVO |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 4.3M |
| IPO Year | 2008 | 2023 |
| Metric | SBFM | APVO |
|---|---|---|
| Price | $0.17 | $1.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 10.1M | 33.3K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $36,305,891.00 | $3,114,000.00 |
| Revenue This Year | $1.23 | N/A |
| Revenue Next Year | $22.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.11 | N/A |
| 52 Week Low | $0.19 | $0.53 |
| 52 Week High | $21.30 | $10.70 |
| Indicator | SBFM | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 25.50 | 30.88 |
| Support Level | N/A | $1.37 |
| Resistance Level | $1.26 | $1.98 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 0.81 | 10.40 |
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.